Remodeling "cold" tumor immune microenvironment via epigenetic-based therapy using targeted liposomes with in situ formed albumin corona
文献类型：期刊论文
| 作者 | He, Yang5,6,7,8; Fang, Yuefei4,8; Zhang, Meng3,8; Zhao, Yuge8; Tu, Bin7,8; Shi, Mingjie8; Muhitdinov, Bahtiyor2,8; Asrorov, Akmal2,8; Xu, Qin4; Huang, Yongzhuo1,6,7,8
|
| 刊名 | ACTA PHARMACEUTICA SINICA B
 |
| 出版日期 | 2022-04-01 |
| 卷号 | 12期号:4页码:2057-2073 |
| 关键词 | Tumor immune microenvironment Tumor-associated macrophage Epigenetic therapy Immune checkpoint Angiogenesis Panobinostat JQ1 Liposome |
| ISSN号 | 2211-3835 |
| DOI | 10.1016/j.apsb.2021.09.022 |
| 通讯作者 | Huang, Yongzhuo(yzhuang@simm.ac.cn) |
| 英文摘要 | There is a close connection between epigenetic regulation, cancer metabolism, and immunology. The combination of epigenetic therapy and immunotherapy provides a promising avenue for cancer management. As an epigenetic regulator of histone acetylation, panobinostat can induce histone acetylation and inhibit tumor cell proliferation, as well as regulate aerobic glycolysis and reprogram intratumoral immune cells. JQ1 is a BRD4 inhibitor that can suppress PD-L1 expression. Herein, we proposed a chemo-free, epigenetic-based combination therapy of panobinostat/JQ1 for metastatic colorectal cancer. A novel targeted binary-drug liposome was developed based on lactoferrin-mediated binding with the LRP-1 receptor. It was found that the tumor-targeted delivery was further enhanced by in situ formation of albumin corona. The lactoferrin modification and endogenous albumin adsorption contribute a dual-targeting effect on the receptors of both LRP-1 and SPARC that were overexpressed in tumor cells and immune cells (e.g., tumor-associated macrophages). The targeted liposomal therapy was effective to suppress the crosstalk between tumor metabolism and immune evasion via glycolysis inhibition and immune normalization. Consequently, lactic acid production was reduced and angiogenesis inhibited; TAM switched to an anti-tumor phenotype, and the anti-tumor function of the effector CD8 thorn T cells was reinforced. The strategy provides a potential method for remodeling the tumor immune microenvironment (TIME). 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| WOS关键词 | ANTITUMOR IMMUNITY ; PROTEIN CORONA ; CANCER ; INHIBITORS ; MACROPHAGES ; METABOLISM ; MECHANISMS ; EXPRESSION ; CODELIVERY ; RESISTANCE |
| 资助项目 | National Special Project for Signif-icant Drugs Development, China[2018ZX09711002-010-002] ; National Natural Science Foundation of China (NSFC), China[81925035] ; National Natural Science Foundation of China (NSFC), China[82050410361] ; National Natural Science Foundation of China (NSFC), China[81521005] ; Shanghai Collaborative Innovation Group, China[SSMU-ZDCX20180701] ; Shanghai Sci-Tech Innovation Action Plan, China[19431903100] ; Chinese Academy of Sciences (CAS) PIFI Fellowship, China[2019PB0076] ; Chinese Academy of Sciences (CAS) PIFI Fellowship, China[2020PB0094] ; Belt & Road Young Scientist Award (Shanghai, China)[18430740800] |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000806265900001 |
| 出版者 | INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/301474]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Huang, Yongzhuo |
| 作者单位 | 1.Natl Med Prod Adm, Key Lab Qual Res & Evaluat Pharmaceut Excipients, Shanghai 201203, Peoples R China 2.Acad Sci Uzbek, Inst Bioorgan Chem, Tashkent 100125, Uzbekistan 3.Zhejiang Univ, Sch Med, Womens Hosp, Hangzhou 310006, Peoples R China 4.Guangzhou Univ Chinese Med, Artemisinin Res Ctr, Guangzhou 510450, Peoples R China 5.Zhengzhou Univ, Dept Pharm, Affiliated Hosp 1, Zhengzhou 450052, Peoples R China 6.Chinese Acad Sci, Zhongshan Inst Drug Discovery, Zhongshan 528437, Peoples R China 7.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 8.Chinese Acad Sci, Shanghai Inst Mat Medica, State Key Lab Drug Res, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | He, Yang,Fang, Yuefei,Zhang, Meng,et al. Remodeling "cold" tumor immune microenvironment via epigenetic-based therapy using targeted liposomes with in situ formed albumin corona[J]. ACTA PHARMACEUTICA SINICA B,2022,12(4):2057-2073. |
| APA | He, Yang.,Fang, Yuefei.,Zhang, Meng.,Zhao, Yuge.,Tu, Bin.,...&Huang, Yongzhuo.(2022).Remodeling "cold" tumor immune microenvironment via epigenetic-based therapy using targeted liposomes with in situ formed albumin corona.ACTA PHARMACEUTICA SINICA B,12(4),2057-2073. |
| MLA | He, Yang,et al."Remodeling "cold" tumor immune microenvironment via epigenetic-based therapy using targeted liposomes with in situ formed albumin corona".ACTA PHARMACEUTICA SINICA B 12.4(2022):2057-2073. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。